Invalidation of dieckol and 1,2,3,4,6-pentagalloylglucose (PGG) as SARS-CoV-2 main protease inhibitors and the discovery of PGG as a papain-like protease inhibitor

Characteristics of SARS-CoV-2 and COVID-19

Hu, B., Guo, H., Zhou, P., & Shi, Z.-L. (2021) · Nature Reviews Microbiology · doi:10.1038/s41579-020-00459-7 · Cited by 5,291 · see citing works

Structure of Mpro from SARS-CoV-2 and discovery of its inhibitors

Jin, Z., Du, X., Xu, Y., Deng, Y., Liu, M., Zhao, Y., Zhang, B., Li, X., Zhang, L., Peng, C., et al. (2020) · Nature · doi:10.1038/s41586-020-2223-y · Cited by 4,432 · see citing works

A SARS-CoV-2 protein interaction map reveals targets for drug repurposing

Gordon, D. E., Jang, G. M., Bouhaddou, M., Xu, J., Obernier, K., White, K. M., O’Meara, M. J., Rezelj, V. V., Guo, J. Z., Swaney, D. L., et al. (2020) · Nature · doi:10.1038/s41586-020-2286-9 · Cited by 4,405 · see citing works

Coronavirus biology and replication: implications for SARS-CoV-2

V’kovski, P., Kratzel, A., Steiner, S., Stalder, H., & Thiel, V. (2020) · Nature Reviews Microbiology · doi:10.1038/s41579-020-00468-6 · Cited by 3,175 · see citing works

Broad-spectrum antiviral GS-5734 inhibits both epidemic and zoonotic coronaviruses

Sheahan, T. P., Sims, A. M., Graham, R. L., Menachery, V. D., Gralinski, L. E., Case, J. B., Leist, S. R., Pyrć, K., Feng, J. Y., Trantcheva, I., et al. (2017) · Science Translational Medicine · doi:10.1126/scitranslmed.aal3653 · Cited by 1,575 · see citing works

Therapeutic efficacy of the small molecule GS-5734 against Ebola virus in rhesus monkeys

Warren, T. K., Jordan, R., Lo, M. K., Ray, A. S., Mackman, R. L., Soloveva, V., Siegel, D. S., Perron, M. J., Bannister, R. M., Hui, H. C., et al. (2016) · Nature · doi:10.1038/nature17180 · Cited by 1,561 · see citing works

Remdesivir: A Review of Its Discovery and Development Leading to Emergency Use Authorization for Treatment of COVID-19

Eastman, R. T., Roth, J. S., Brimacombe, K. R., Simeonov, A. M., Shen, M., Patnaik, S., & Hall, M. D. (2020) · ACS Central Science · doi:10.1021/acscentsci.0c00489 · Cited by 951 · see citing works

Boceprevir, GC-376, and calpain inhibitors II, XII inhibit SARS-CoV-2 viral replication by targeting the viral main protease

Ma, C., Sacco, M. D., Hurst, B., Townsend, J. A., Hu, Y., Szeto, T., Zhang, X., Tarbet, B., Marty, M. T., Chen, Y., et al. (2020) · Cell Research · doi:10.1038/s41422-020-0356-z · Cited by 880 · see citing works

Both Boceprevir and GC376 efficaciously inhibit SARS-CoV-2 by targeting its main protease

Fu, L., Ye, F., Feng, Y., Yu, F., Wang, Q., Wu, Y., Zhao, C., Sun, H., Huang, B., Niu, P., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-18233-x · Cited by 544 · see citing works

Structure of papain-like protease from SARS-CoV-2 and its complexes with non-covalent inhibitors

Osipiuk, J., Azizi, S., Dvorkin, S., Endres, M. J., Jedrzejczak, R. P., Jones, K. A., Kang, S., Kathayat, R. S., Kim, Y., Lisnyak, V. G., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-21060-3 · Cited by 471 · see citing works

Feline coronavirus drug inhibits the main protease of SARS-CoV-2 and blocks virus replication

Vuong, W., Khan, M. B., Fischer, C., Arutyunova, E. I., Lamer, T., Shields, J. A., Saffran, H. A., McKay, R. T., van Belkum, M. J., Joyce, M., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-18096-2 · Cited by 455 · see citing works

Structure and inhibition of the SARS-CoV-2 main protease reveal strategy for developing dual inhibitors against M pro and cathepsin L

Sacco, M. D., Ma, C., Lagarias, P. I., Gao, A., Townsend, J. A., Meng, X., Dube, P. H., Zhang, X., Hu, Y., Kitamura, N., et al. (2020) · Science Advances · doi:10.1126/sciadv.abe0751 · Cited by 401 · see citing works

Therapeutically administered ribonucleoside analogue MK-4482/EIDD-2801 blocks SARS-CoV-2 transmission in ferrets

Cox, R. M., Wolf, J. D., & Plemper, R. K. (2020) · Nature Microbiology · doi:10.1038/s41564-020-00835-2 · Cited by 391 · see citing works

Characterization of orally efficacious influenza drug with high resistance barrier in ferrets and human airway epithelia

Toots, M., Yoon, J.-J., Cox, R. M., Hart, M., Sticher, Z. M., Makhsous, N., Plesker, R., Barrena, A. H., Reddy, P. G., Mitchell, D. G., et al. (2019) · Science Translational Medicine · doi:10.1126/scitranslmed.aax5866 · Cited by 316 · see citing works

Drug Development and Medicinal Chemistry Efforts toward SARS‐Coronavirus and Covid‐19 Therapeutics

Ghosh, A. K., Brindisi, M., Shahabi, D., Chapman, M. E., & Mesecar, A. D. (2020) · ChemMedChem · doi:10.1002/cmdc.202000223 · Cited by 306 · see citing works

Masitinib is a broad coronavirus 3CL inhibitor that blocks replication of SARS-CoV-2

Drayman, N., DeMarco, J. K., Jones, K. A., Azizi, S., Froggatt, H. M., Tan, K., Maltseva, N., Chen, S., Nicolaescu, V. I., Dvorkin, S., et al. (2021) · Science · doi:10.1126/science.abg5827 · Cited by 285 · see citing works

Ebselen, Disulfiram, Carmofur, PX-12, Tideglusib, and Shikonin Are Nonspecific Promiscuous SARS-CoV‑2 Main Protease Inhibitors

Ma, C., Hu, Y., Townsend, J. A., Lagarias, P. I., Marty, M. T., Kolocouris, A., & Wang, J. (2020) · ACS Pharmacology & Translational Science · doi:10.1021/acsptsci.0c00130 · Cited by 273 · see citing works

Inhibition mechanism of SARS-CoV-2 main protease by ebselen and its derivatives

Amporndanai, K., Meng, X., Shang, W., Jin, Z., Rogers, M., Zhao, Y., Rao, Z., Liu, Z., Yang, H., Zhang, L., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-23313-7 · Cited by 257 · see citing works

Disulfiram can inhibit MERS and SARS coronavirus papain-like proteases via different modes

Lin, M.-H., Moses, D. C., Hsieh, C.-H., Cheng, S.-C., Chen, Y., Sun, C., & Chou, C. (2017) · Antiviral Research · doi:10.1016/j.antiviral.2017.12.015 · Cited by 251 · see citing works

Discovery of SARS-CoV-2 Papain-like Protease Inhibitors through a Combination of High-Throughput Screening and a FlipGFP-Based Reporter Assay

Ma, C., Sacco, M. D., Xia, Z., Lambrinidis, G., Townsend, J. A., Hu, Y., Meng, X., Szeto, T., Ba, M., Zhang, X., et al. (2021) · ACS Central Science · doi:10.1021/acscentsci.1c00519 · Cited by 201 · see citing works

Dieckol, a SARS-CoV 3CLpro inhibitor, isolated from the edible brown algae Ecklonia cava

Park, J. Y., Kim, J. H., Kwon, J. M., Kwon, H., Jeong, H. J., Kim, Y. M., Kim, D., Lee, W. S., & Ryu, Y. B. (2013) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2013.04.026 · Cited by 188 · see citing works

Discovery of Di- and Trihaloacetamides as Covalent SARS-CoV-2 Main Protease Inhibitors with High Target Specificity

Ma, C., Xia, Z., Sacco, M. D., Hu, Y., Townsend, J. A., Meng, X., Choza, J. I., Tan, H., Jang, J., Gongora, M. V., et al. (2021) · Journal of the American Chemical Society · doi:10.1021/jacs.1c08060 · Cited by 177 · see citing works

High-throughput screening identifies established drugs as SARS-CoV-2 PLpro inhibitors

Zhao, Y., Du, X., Duan, Y., Pan, X., Sun, Y., You, T., Han, L., Jin, Z., Shang, W., Yu, J., et al. (2021) · Protein & Cell · doi:10.1007/s13238-021-00836-9 · Cited by 155 · see citing works

Identification of ebselen and its analogues as potent covalent inhibitors of papain-like protease from SARS-CoV-2

Węglarz‐Tomczak, E., Tomczak, J. M., Talma, M., Burda‐Grabowska, M., Giurg, M., & Brul, S. (2021) · Scientific Reports · doi:10.1038/s41598-021-83229-6 · Cited by 127 · see citing works

Multi-targeting of functional cysteines in multiple conserved SARS-CoV-2 domains by clinically safe Zn-ejectors

Sargsyan, K., Lin, C.-C., Chen, T., Grauffel, C., Chen, Y.-P., Yang, W., Yuan, H. S., & Lim, C. (2020) · Chemical Science · doi:10.1039/d0sc02646h · Cited by 104 · see citing works

Development of a Fluorescence-Based, High-Throughput SARS-CoV-2 3CL pro Reporter Assay

Froggatt, H. M., Heaton, B. E., & Heaton, N. S. (2020) · Journal of Virology · doi:10.1128/jvi.01265-20 · Cited by 101 · see citing works

Validation and invalidation of SARS-CoV-2 main protease inhibitors using the Flip-GFP and Protease-Glo luciferase assays

Ma, C., Tan, H., Choza, J., Wang, Y., & Wang, J. (2022) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2021.10.026 · Cited by 86 · see citing works

A review on potential of natural products in the management of COVID-19

Chakravarti, R., Singh, R., Ghosh, A., Dey, D., Sharma, P., Ravichandiran, V., Roy, S., & Ghosh, D. (2021) · RSC Advances · doi:10.1039/d1ra00644d · Cited by 80 · see citing works

6-Thioguanine blocks SARS-CoV-2 replication by inhibition of PLpro

Swaim, C. D., Dwivedi, V., Perng, Y.-C., Zhao, X. M., Canadeo, L. A., Harastani, H., Darling, T. L., Boon, A. C. M., Lenschow, D. J., Kulkarni, V., et al. (2021) · iScience · doi:10.1016/j.isci.2021.103213 · Cited by 71 · see citing works

Natural Products with Potential to Treat RNA Virus Pathogens Including SARS-CoV-2

Christy, M. P., Uekusa, Y., Gerwick, L. G., & Gerwick, W. H. (2020) · Journal of Natural Products · doi:10.1021/acs.jnatprod.0c00968 · Cited by 64 · see citing works

The inhibitory effects of PGG and EGCG against the SARS-CoV-2 3C-like protease

Chiou, W.-C., Chen, J., Chen, Y., Yang, J., Hwang, L., Lyu, Y.-S., Yang, H.-Y., & Huang, C. (2021) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2020.12.106 · Cited by 61 · see citing works

Validation and Invalidation of SARS-CoV-2 Papain-like Protease Inhibitors

Ma, C., & Wang, J. (2022) · ACS Pharmacology & Translational Science · doi:10.1021/acsptsci.1c00240 · Cited by 56 · see citing works

1,2,3,4,6-Pentagalloyl Glucose, a RBD-ACE2 Binding Inhibitor to Prevent SARS-CoV-2 Infection

Chen, R. H., Yang, L., Hamdoun, S., Chung, S. K., Lam, C. W.-K., Zhang, K. X., Guo, X., Xia, C., Law, B. Y. K., & Wong, V. K. W. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.634176 · Cited by 54 · see citing works

Dipyridamole, chloroquine, montelukast sodium, candesartan, oxytetracycline, and atazanavir are not SARS-CoV-2 main protease inhibitors

Ma, C., & Wang, J. (2021) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2024420118 · Cited by 54 · see citing works

Development of a simple and miniaturized sandwich-like fluorescence polarization assay for rapid screening of SARS-CoV-2 main protease inhibitors

Yan, G., Li, D., Lin, Y., Fu, Z., Qi, H., Liu, X., Zhang, J., Si, S., & Chen, Y. (2021) · Cell & Bioscience · doi:10.1186/s13578-021-00720-3 · Cited by 46 · see citing works

Drug Repurposing for the SARS‐CoV‐2 Papain‐Like Protease

Cho, C.-C. D., Li, S. G., Lalonde, T. J., Yang, K. S., Yu, G., Qiao, Y., Xu, S., & Liu, W. R. (2021) · ChemMedChem · doi:10.1002/cmdc.202100455 · Cited by 45 · see citing works

Ethacridine inhibits SARS-CoV-2 by inactivating viral particles

Li, X., Lidsky, P. V., Xiao, Y., Wu, C.-T., Garcia-Knight, M., Yang, J., Nakayama, T., Nayak, J. V., Jackson, P. K., Andino, R., et al. (2021) · PLoS Pathogens · doi:10.1371/journal.ppat.1009898 · Cited by 42 · see citing works

Disulfiram: Mechanisms, Applications, and Challenges

Lanz, J., Biniaz-Harris, N., Kuvaldina, M., Jain, S., Lewis, K., & Fallon, B. A. (2023) · Antibiotics · doi:10.3390/antibiotics12030524 · Cited by 125 · see citing works

COVID-19 therapeutics: Small-molecule drug development targeting SARS-CoV-2 main protease

Kronenberger, T., Laufer, S., & Pillaiyar, T. (2023) · Drug Discovery Today · doi:10.1016/j.drudis.2023.103579 · Cited by 72 · see citing works

On the origins of SARS-CoV-2 main protease inhibitors

Janin, Y. L. (2023) · RSC Medicinal Chemistry · doi:10.1039/d3md00493g · Cited by 57 · see citing works

Ebselen derivatives inhibit SARS-CoV-2 replication by inhibition of its essential proteins: PLpro and Mpro proteases, and nsp14 guanine N7-methyltransferase

Żmudziński, M., Rut, W., Olech, K., Granda, J. M., Giurg, M., Burda‐Grabowska, M., Kaleta, R., Zgarbová, M., Kasprzyk, R., Zhang, L., et al. (2023) · Scientific Reports · doi:10.1038/s41598-023-35907-w · Cited by 82 · see citing works

Progress in Research on Inhibitors Targeting SARS-CoV-2 Main Protease (M pro )

Yang, Y., Luo, Y., Zhang, C., Xiang, Y., Bai, X., Zhang, D., Fu, Z., Hao, R.-B., & Liu, X. (2024) · ACS Omega · doi:10.1021/acsomega.4c03023 · Cited by 33 · see citing works

Structure-based design of SARS-CoV-2 papain-like protease inhibitors

Jadhav, P., Huang, B., Osipiuk, J., Zhang, X., Tan, H., Tesar, C., Endres, M. J., Jedrzejczak, R. P., Tan, B., Deng, X., et al. (2023) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2023.116011 · Cited by 29 · see citing works

Stand Up to Stand Out: Natural Dietary Polyphenols Curcumin, Resveratrol, and Gossypol as Potential Therapeutic Candidates against Severe Acute Respiratory Syndrome Coronavirus 2 Infection

Wang, Z., Song, X.-Q., Xu, W., Lei, S., Zhang, H., & Yang, L. (2023) · Nutrients · doi:10.3390/nu15183885 · Cited by 20 · see citing works

A Patent Review on SARS Coronavirus Papain‐Like Protease (PL pro ) Inhibitors

Chia, C. S. B., & Lim, S. P. (2023) · ChemMedChem · doi:10.1002/cmdc.202300216 · Cited by 17 · see citing works

Therapeutic cysteine protease inhibitors: a patent review (2018–present)

Barchielli, G., Capperucci, A., & Tanini, D. (2024) · Expert Opinion on Therapeutic Patents · doi:10.1080/13543776.2024.2327299 · Cited by 17 · see citing works

New insights in the mechanism of the SARS-CoV-2 Mpro inhibition by benzisoselenazolones and diselenides

Sancineto, L., Mangiavacchi, F., Dąbrowska, A., Pacuła‐Miszewska, A. J., Obieziurska‐Fabisiak, M., Scimmi, C., Ceccucci, V., Kong, J., Zhao, Y., Ciancaleoni, G., et al. (2024) · Scientific Reports · doi:10.1038/s41598-024-75519-6 · Cited by 16 · see citing works

FlipGFP protease assay for evaluating in vitro inhibitory activity against SARS-CoV-2 Mpro and PLpro

Tan, H., Hu, Y., & Wang, J. (2023) · STAR Protocols · doi:10.1016/j.xpro.2023.102323 · Cited by 11 · see citing works

Methyl rosmarinate is an allosteric inhibitor of SARS-CoV-2 3 CL protease as a potential candidate against SARS-cov-2 infection

Li, H., Sun, M., Lei, F., Liu, J., Chen, X., Li, Y., Wang, Y., Lu, J., Yu, D., Gao, Y., et al. (2024) · Antiviral Research · doi:10.1016/j.antiviral.2024.105841 · Cited by 10 · see citing works

COVID-19 associated thyroid dysfunction and other comorbidities and its management using phytochemical-based therapeutics: a natural way

Parihar, A., Malviya, S., Khan, R., Kaushik, A. K., & Mostafavi, E. (2023) · Bioscience Reports · doi:10.1042/bsr20230293 · Cited by 8 · see citing works

Development of a Fluorescence Polarization Assay for the SARS-CoV-2 Papain-like Protease

Li, K., Jadhav, P., Wen, Y., Tan, H., & Wang, J. (2025) · ACS Pharmacology & Translational Science · doi:10.1021/acsptsci.4c00642 · Cited by 5 · see citing works

Structural Basis and Inhibitor Development of SARS-CoV-2 Papain-like Protease

Wang, J., Xu, Y., Yang, Y., Zhang, B. X., Chen, S., Li, Z., Zhu, H., Yang, H. Y., Wang, H., Zhou, Y., et al. (2026) · Molecules · doi:10.3390/molecules31030474 · Cited by 4 · see citing works

Sumac Polyphenols as Pan-Herpesvirus Inhibitors

Salikhov, S. I., Ощепкова, Ю. И., Ziyavitdinov, J. F., Ashurov, J., Berdiev, N. S., Kolundin, M. S., Gaidarov, A. O., Turgiev, A. S., Иванович, Ю. К., Larichev, V. F., et al. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms262110398 · Cited by 3 · see citing works

Inhibitors of the RBD-ACE-2 Found among a Wide Range of Dyes by the Immunoassay Method

Mordvinova, E. D., Никитина, П. А., Yarovaya, О. I., Volosnikova, E. A., Murashkin, D. E., Исаева, А. А., Koldaeva, T. Y., Perevalov, V. P., Salakhutdinov, N. F., & Щербаков, Д. Н. (2023) · Chemosensors · doi:10.3390/chemosensors11020135 · Cited by 3 · see citing works

Off-label and repurposed use of disulfiram beyond alcohol dependence: A systematic review of clinical and preclinical evidence

Benkő, B.-M., De Brito Parreirinha, N. S., Sebe, I., & Zelkó, R. (2026) · iScience · doi:10.1016/j.isci.2026.115441 · Cited by 2 · see citing works

Production of Envelope Protein-Based Virus-like Particles of DENV-2 in E. coli and Investigation of Their Binding Interactions with Gallic Acid Derivatives of Glucose as Potential Drug Candidates

Sharma, A., Nimesh, S., & Tapryal, S. (2025) · ACS Omega · doi:10.1021/acsomega.5c02548 · Cited by 1 · see citing works

Peptide Mold: A Novel Strategy for Mapping Potential Binding Sites in Protein TargetsPreprint

Bagwe, P. V., Jagtap, Y., Ghegade, V. N., Machhar, J. S., Martis, E. A. F., Joshi, S. V., & Kharkar, P. S. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.02.28.582665

BindingDB Entry 50021419: Structure-based design of SARS-CoV-2 papain-like protease inhibitors.

BindingDB (2025) · UC San Diego · doi:10.7270/q2639vdn

Discovery of new non-covalent and covalent inhibitors targeting SARS-CoV-2 papain-like protease and main protease

Liu, W., Wang, J., Wang, S., Yue, K., Hu, Y., Liu, X., Wang, L., Wan, S., & Xu, X. (2023) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2023.106830 · Cited by 13 · see citing works

High-throughput screening of SARS-CoV-2 main and papain-like protease inhibitors

Zang, Y., Su, M., Wang, Q., Cheng, X., Zhang, W., Zhao, Y., Chen, T., Jiang, Y., Shen, Q., Du, J., et al. (2022) · Protein & Cell · doi:10.1093/procel/pwac016 · Cited by 31 · see citing works

[Identifying SARS-CoV-2 main protease inhibitors by a novel sandwich-like fluorescence polarization screening assay].

Yan, H., Yan, G., Qi, H., Liu, Z., Liu, X., Liu, X., Li, N., & Chen, Y. (2022) · PubMed · doi:10.13345/j.cjb.210949 · Cited by 2 · see citing works

Critical Review of Plant-Derived Compounds as Possible Inhibitors of SARS-CoV-2 Proteases: A Comparison with Experimentally Validated Molecules

Guerra, Y., Celi, D., Cueva, P., Pérez‐Castillo, Y., Giampieri, F., Álvarez-Suárez, J. M., & Tejera, E. (2022) · ACS Omega · doi:10.1021/acsomega.2c05766 · Cited by 15 · see citing works

Validation and Invalidation of SARS-CoV-2 Papain-like Protease Inhibitors

Ma, C., & Wang, J. (2022) · ACS Pharmacology & Translational Science · doi:10.1021/acsptsci.1c00240 · Cited by 56 · see citing works